secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2021-12-16T23:59:59+00:00
Accession:  0001564590-21-060582
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma awards incentive stock options to four executives
----------------------------------------------------------------

- CEO Michael Bristow received 95,000 options; COO Keuer 35,000; GC Ozeroff 27,500; CFO Dekker 17,700.
- Exercise price $2.29 per share, closing price on December 14, 2021; vesting in 36 equal monthly installments.
- In a change of control, 50% of unvested options accelerate; remainder vest on earlier of one year or involuntary termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000156459021060582/0001564590-21-060582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000156459021060582/abio-8k_20211214.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-060582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer